person · Reporting owner
Cunningham Timothy M.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | interim CFO | February 17, 2021 | February 26, 2021 |
| Neuphoria Therapeutics Inc.BNOX · Entity 7639 | Chief Financial Officer | July 01, 2024 | July 08, 2024 |
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Chief Financial Officer | April 22, 2020 | April 24, 2020 |
| Peak Bio, Inc.PKBO · Entity 85431 | Acting Chief Financial Officer | November 01, 2022 | November 04, 2022 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | See Remarks | May 16, 2024 | May 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date February 17, 2021 · Filed February 26, 2021
This filing explicitly reported no securities owned.
Neuphoria Therapeutics Inc.
Report date July 01, 2024 · Filed July 08, 2024
This filing explicitly reported no securities owned.
Organogenesis Holdings Inc.
Report date April 22, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 27,847 |
Reported balance
After 2020-04-22 transaction · row 1
1 source rowRow 1 · 2020-04-22 · Grant · Acquired 27,847 · Balance 27,847 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2030-04-22 | Direct | 183,424 |
Reported balance
After 2020-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-22 · Grant · Acquired 183,424 · Balance 183,424 F2: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020.
F2: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020.
Peak Bio, Inc.
Report date November 01, 2022 · Filed November 04, 2022
This filing explicitly reported no securities owned.
Rein Therapeutics, Inc.
Report date May 16, 2024 · Filed May 16, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2020 Filed Apr 24, 2020 11:32 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 183,424 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000010 · edgar.xml · derivative · entry 2 Cunningham Timothy M. · CIK 0001757426 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,424 Underlying: Class A Common Stock · 183,424 shares Expires 2030-04-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:32 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 27,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000010 · edgar.xml · nonDerivative · entry 1 Cunningham Timothy M. · CIK 0001757426 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,847 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:52 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 559,620 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000037 · edgar.xml · derivative · entry 1 Cunningham Timothy M. · CIK 0001757426 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,620 Underlying: Common Stock · 559,620 shares Expires 2027-05-04 F2 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 275,675 shares of common stock of Organogenesis for $7.01 per share. F1 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on August 22, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.